Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE phase 3 study of VRDN-001 in thyroid eye disease
NL-OMON51573Phase 3Recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of veligrotug in Graves Orbitopathy (GO) (7 arms), sponsored by Viridian Therapeutics. Primary endpoints: Proptosis responder rate at Week 15 and Overall responder rate at Week 15. Started Aug 2023; status: recruiting.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NL-OMON51573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51573.